The pharmaceutical giant Pfizer said Tuesday that a new coronavirus vaccine could be tested as early as next week — with the potential for emergency use by fall, a report said Tuesday.
“This is a crisis right now, and a solution is desperately needed by all,” Pfizer Chief Executive Albert Bourla told the Wall Street Journal.
Pfizer is working with German-based BioNtech to deliver the possible vaccine. Clinical trials on human volunteers in Germany have already started.
Health regulators in the US may approve testing the vaccine on humans by next week, Bourla told the paper.
If that timeline holds true, study results could be delivered within a month. Then, with favorable testing outcomes, the vaccine may be ready to distribute in emergency cases by the fall, Bourla said.
The New York-based corporation has invested $650 million into developing and possibly manufacturing the vaccine.
“You can imagine the demand for something like that will be extremely, extremely high,” Bourla told the Journal.
But the odds of developing a successful vaccine are slim, with just 6 percent of them becoming market-ready after a series of strict tests, the report said, citing a 2013 study published by PLOS ONE.
Related Post:
- Pfizer coronavirus vaccine could be ready for emergency use by this fall
- US finally approves Pfizer/BioNTech Covid-19 vaccine for emergency use
- Pfizer, BioNTech dose first coronavirus vaccine trial
- Healthcare worker with no history of drug allergies suffers serious reaction after getting Pfizer’s coronavirus vaccine
- ‘Johnson and Johnson’ Approved As COVID-19 Vaccine For Emergency Use
- “Don’t rush, We’re Coming up with Vaccine that will work” -Trump reveals when Coronavirus vaccine will be ready
- Trump claims coronavirus vaccine could be ready as early as October
- Potential coronavirus vaccine enters clinical trial, could be ready by end of year
- Rutgers to enroll 200 kids to take part in Pfizer COVID vaccine trial